Resonance Health Stock

Resonance Health EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Resonance Health (RHT.AX) as of Jul 26, 2026 is -11.09. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -30.69 — a change of -63.85% (higher).

EV/EBIT

-11.09

YoY

-63.85%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Resonance Health is 2026 -11.09 . EV/EBIT (Enterprise Value to EBIT) of Resonance Health was 2025 -30.69 . It decreases by -63.85% higher compared to the previous year.

The Resonance Health EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-98.05 base
Jan 1, 2019
100.98 base
Jan 1, 2020
-91.14 base
Jan 1, 2021
280.52 base
Jan 1, 2022
-15.64 base
Jan 1, 2023
-18.23 base
Jan 1, 2024
-39.43 base
Jan 1, 2025
-12.12 base
YEARPRICE-TO-EBIT
2025 -12.12
2024 -39.43
2023 -18.23
2022 -15.64
2021 280.52
2020 -91.14
2019 100.98
2018 -98.05
2017 -15.42
2016 -23.47
2015 82.62
2014 149.06
2013 -43.74
2012 -14.75
2011 -12.97
2010 -34.45
2009 17.67
2008 -10.08
2007 -4.43
2006 -0.90
Access this data via the Eulerpool API

Resonance Health Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Resonance Health's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Resonance Health's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Resonance Health's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Resonance Health grows earnings faster than its peers.

Resonance Health Stock analysis

What does Resonance Health do? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resonance Health stock

EV/EBIT (Enterprise Value to EBIT) of Resonance Health is -11.09 in 2026.

Access this data via the Eulerpool API

Valuation — Resonance Health

All Key Metrics — Resonance Health